

Quality-Data Code Submission Error Report 2nd Quarter 2010 Physician Quality Reporting Initiative

Report Date: 09/20/2010

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

Column Definitions:

- Total QDCs Reported - Number of QDC submissions for a measure whether or not the QDC submission was valid and appropriate for a measure.
- Total Valid QDCs Reported - Number of valid and appropriate QDC submissions for a measure.
- % Valid – Percentage of Total Valid QDCs Reported divided by Total QDCs Reported.
- Total QDCs Reported on Eligible Cases – Number of valid or invalid QDCs reported on eligible cases meeting the measure's denominator criteria.
- Patient Age Mismatch - Patient did not meet age requirements for the measure.
- Patient Gender Mismatch - Patient did not meet gender requirement for the measure.
- Incorrect HCPCS - Incorrect HCPCS code for the measure - Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis - Incorrect diagnosis code on claim - Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis and HCPCS - Combination of incorrect HCPCS code and incorrect diagnosis code on claim - Patient claim did not meet denominator eligibility per measure specifications.
- Only QDC on Claim - Patient claim missing a qualifying denominator code (all line items contained only QDCs).
- Only QDC and Incorrect Diagnosis - Combination of missing qualifying denominator code and qualifying diagnosis code on the claim.
- Resubmitted QDCs - Submissions invalid due to resubmission of claims simply for the purpose of adding QDCs.
- Unattributed/No NPI - Submissions where the rendering NPI was missing.

How to Read the Quality-Data Code Submission Error Report by Measure:

Using Measure #47-Advance Care Plan as an example, we find the following information as we read across each column:

379,781 QDC submissions were received for this measure, 327,136 of which were considered valid. Therefore, the Valid Submission Rate is 86.14%. The rest of the columns explain reasons for invalid submissions for measure #47. We see that 17,210 (4.53%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 35,024 (9.22%) submissions were for patient encounters that are not listed in the denominator; this measure applies to all Medicare Part B beneficiaries regardless of diagnosis; 4,155 (1.09%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, NPI/TIN. There were no submissions with a combination of QDC-only and diagnosis mismatch and no QDC resubmissions for this measure. There were also no submissions which lacked an NPI in the rendering provider ID field on the claim.

Analysis Findings Include:

1. The top 5 measures with the highest percentage of valid QDCs codes submitted were:

#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy (97.44%),
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity (97.22%),
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (97.22%),
#173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening (97.05%), and
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening (96.87%).

2. The 5 measures with the lowest percentage of Valid QDCs submitted (with at least 1 eligible instance) were:

#66 Appropriate Testing for Children with Pharyngitis (0.17%),
#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (0.21%),
#65 URI: Appropriate Treatment for Children (0.25%),
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility (1.57%), and
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection (1.59%),

3. The measures that are in the top 25% of all measures on Total QDCs Reported and in the bottom 25% for percentage of Valid QDCs are: #20 Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician and #55 ECG Performed for Syncope. Both of these measures share QDCs with other current measures.

4. The top 5 measures with the highest percentage of claims with QDCs only (no denominator-eligible codes) were:

#134 Screening for Clinical Depression (9.34%),
#112 Screening Mammography (5.77%),
#155 Falls: Plan of Care (4.36%),
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility (4.00%), and
#181 Elder Maltreatment Screen and Follow-Up Plan (3.86%).

5. The 5 measures with the highest rate of Diagnosis errors were:

#40 Osteoporosis: Management Following Fracture (91.09%),
#122 CKD: Blood Pressure Management (64.09%),
#55 ECG Performed for Syncope (58.14%),
#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days (46.67%), and
#121 CKD: Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile) (40.47%).

6. The top 5 measures with the highest rate of HCPCS errors were:

#20 Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician (91.40%),
#45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (68.23%),
#181 Elder Maltreatment Screen and Follow-Up Plan (46.42%),
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery (38.47%), and
#43 Use of IMA in CABG Surgery (37.17%).

7. The 5 measures with the highest rate of patient gender errors were:
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older (3.99%),
#49 Characterization of UI in Women Aged 65 Years and Older (3.43%),
#50 Plan of Care for UI in Women Aged 65 Years and Older (3.33%),
#39 Osteoporosis: Screening or Therapy for Women Aged 65 Years and Older (3.03%), and
#112 Screening Mammography (1.58%).

8. Overall, the percentage of reported instances with missing NPIs was 0.00%.

Please note: Modifications were made to the analytic code that identifies and selects qualifying HCPCS codes for some of the procedure-type measures. The counts of Reporting Denominator and Valid QDCs Reported for those measures decreased from the 1st quarter report to the 2nd quarter report. The measures affected were numbers 10, 21, 22, 99, 100, 146, 157, 172, and 185.

Topic Measure	QDC Submission Attempts			Total QDCs Reported on Eligible Cases	Denominator Mismatch ²												Resubmitted QDCs ¹		Unattributed (No NPI) ³	
	Total QDCs Reported ⁴	Total Valid QDCs Reported ⁵	% Valid		Patient Age Mismatch ⁶		Patient Gender Mismatch ⁷		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim					
	#	#	%		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Advance Care Plan																				
#47 Advance Care Plan	379,781	327,136	86.14%	340,602	17,210	4.53%	0	0.00%	35,024	9.22%	0	0.00%	0	0.00%	4,155	1.09%	0	0.00%	0	0.00%
Anesthesia																				
#193 Preoperative Temperature Management	541,116	504,489	93.23%	518,454	0	0.00%	0	0.00%	20,853	3.82%	0	0.00%	0	0.00%	2,009	0.37%	0	0.00%	0	0.00%
Arthritis-Osteoarthritis																				
#109 Patients with OA with an Assessment of Pain and Function	37,018	30,934	83.56%	30,938	0	0.00%	0	0.00%	17	0.05%	3,417	9.23%	823	2.00%	172	0.46%	177	0.48%	0	0.00%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	33,662	23,854	70.86%	23,857	0	0.00%	0	0.00%	13	0.04%	7,313	21.72%	376	1.00%	169	0.50%	291	0.86%	0	0.00%
Arthritis-Rheumatoid																				
#108 DMARD Therapy in Rheumatoid Arthritis	21,164	20,159	95.25%	20,177	0	0.00%	0	0.00%	212	1.00%	710	3.35%	13	0.00%	37	0.17%	51	0.24%	10	0.05%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	5,384	4,831	89.73%	5,260	0	0.00%	0	0.00%	41	0.76%	64	1.19%	3	0.00%	6	0.11%	6	0.11%	10	0.19%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	5,867	5,704	97.22%	5,705	0	0.00%	0	0.00%	29	0.49%	118	2.01%	5	0.00%	7	0.12%	9	0.15%	0	0.00%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	6,895	6,666	96.68%	6,668	0	0.00%	0	0.00%	36	0.52%	178	2.58%	3	0.00%	8	0.12%	10	0.15%	0	0.00%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	4,169	4,053	97.22%	4,064	0	0.00%	0	0.00%	20	0.48%	77	1.85%	2	0.00%	6	0.14%	4	0.10%	0	0.00%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	4,111	3,948	96.04%	4,014	0	0.00%	0	0.00%	24	0.58%	62	1.51%	4	0.00%	7	0.17%	4	0.10%	0	0.00%
Asthma																				
#53 Pharmacologic Therapy	2,460	397	16.14%	437	1,984	80.65%	0	0.00%	14	0.57%	23	0.93%	1,895	77.00%	1	0.04%	91	3.70%	0	0.00%
#64 Asthma Assessment	1,693	232	13.70%	232	1,443	85.23%	0	0.00%	7	0.41%	10	0.59%	1,374	81.00%	0	0.00%	71	4.19%	0	0.00%
Audiology																				
#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	467	1	0.21%	1	0	0.00%	0	0.00%	1	0.21%	5	1.07%	458	98.00%	0	0.00%	3	0.64%	0	0.00%
#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	30	7	23.33%	8	0	0.00%	0	0.00%	0	0.00%	14	46.67%	8	27.00%	0	0.00%	0	0.00%	0	0.00%
#190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	311	288	92.60%	294	0	0.00%	0	0.00%	5	1.61%	6	1.93%	2	1.00%	4	1.29%	1	0.32%	0	0.00%
Breast Cancer																				
#71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer	44,721	40,133	89.74%	43,183	0	0.00%	193	0.43%	437	0.98%	722	1.61%	237	1.00%	134	0.30%	25	0.06%	0	0.00%
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	25,247	13,568	53.74%	13,571	0	0.00%	0	0.00%	522	2.07%	9,488	37.58%	1,447	6.00%	111	0.44%	353	1.40%	0	0.00%
#112 Screening Mammography	84,603	54,647	64.59%	54,674	24,608	29.09%	1,334	1.58%	25,045	29.60%	0	0.00%	0	0.00%	4,884	5.77%	0	0.00%	0	0.00%
Branchitis																				
#116 Inappropriate Antibiotic Treatment for Adults	399	90	22.56%	90	282	70.68%	0	0.00%	3	0.75%	19	4.76%	283	71.00%	1	0.25%	4	1.00%	0	0.00%
CAD																				
#5 Oral Antiplatelet Therapy Prescribed for Patients with CAD	513,320	477,208	92.97%	477,208	1	0.00%	0	0.00%	8,407	1.64%	24,089	4.69%	1,166	0.00%	2,087	0.41%	1,343	0.26%	0	0.00%
Cataracts																				
#139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	260,244	249,299	95.79%	249,340	0	0.00%	0	0.00%	9,273	3.56%	0	0.00%	0	0.00%	1,631	0.63%	0	0.00%	0	0.00%
Catheter-Related Bloodstream Infections (CRBSI)																				
#76 Prevention of CRBSI - Central Venous Catheter Insertion Protocol	99,796	88,123	88.30%	88,123	0	0.00%	0	0.00%	11,144	11.17%	0	0.00%	0	0.00%	529	0.53%	0	0.00%	0	0.00%
Chest Pain																				
#54 ECG Performed for Non-Traumatic Chest Pain	665,833	486,276	73.03%	486,280	8,614	1.29%	0	0.00%	17,338	2.60%	146,611	22.02%	13,246	2.00%	1,615	0.24%	2,115	0.32%	0	0.00%
Chiropactic Care																				
#182 Functional Outcome Assessment in Chiropactic Care	29,817	28,178	94.50%	28,178	0	0.00%	0	0.00%	1,434	4.81%	0	0.00%	0	0.00%	205	0.69%	0	0.00%	0	0.00%
Chronic Kidney Disease (CKD)																				
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	11,606	6,593	56.81%	6,593	0	0.00%	0	0.00%	123	1.06%	4,697	40.47%	98	1.00%	52	0.45%	804	6.93%	0	0.00%
#122 Blood Pressure Management	65,580	12,561	19.15%	13,740	0	0.00%	0	0.00%	9	0.01%	42,030	64.09%	4,113	6.00%	479	0.73%	1,781	2.72%	0	0.00%
#123 Plan of Care: Elevated Hemoglobin for Patients Receiving ESAs	18,124	8,494	46.87%	9,262	4	0.02%	0	0.00%	125	0.69%	3,589	19.80%	5,005	28.00%	39	0.22%	853	4.71%	0	0.00%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	15,588	3,409	21.87%	3,409	0	0.00%	0	0.00%	40	0.26%	3,285	21.07%	8,763	56.00%	12	0.08%	859	5.51%	0	0.00%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	7,731	5,037	65.15%	5,037	0	0.00%	0	0.00%	73	0.94%	1,992	25.77%	561	7.00%	31	0.40%	789	10.21%	0	0.00%
Chronic Obstructive Pulmonary Disease (COPD)																				
#51 Spirometry Evaluation	54,397	49,164	90.38%	49,164	0	0.00%	0	0.00%	696	1.28%	4,128	7.59%	150	0.00%	203	0.37%	391	0.72%	0	0.00%
#52 Bronchodilator Therapy	45,967	36,164	78.67%	41,839	0	0.00%	0	0.00%	604	1.31%	3,093	6.73%	146	0.00%	245	0.53%	203	0.44%	0	0.00%
Colon Cancer																				
#72 Chemotherapy for Stage III	13,122	11,691	89.09%	12,287	0	0.00%	0	0.00%	127	0.97%	663	5.05%	19	0.00%	26	0.20%	7	0.05%	0	0.00%
Colorectal Cancer (CRC)																				
#100 CRC Patients with a pT and pN Category and Histologic Grade	24,152	8,568	35.48%	8,568	0	0.00%	0	0.00%	387	1.60%	2,782	11.52%	11,920	49.00%	79	0.33%	514	2.13%	0	0.00%
#113 CRC Screening	217,570	154,963	71.22%	155,042	57,119	26.25%	0	0.00%	58,512	26.89%	0	0.00%	0	0.00%	4,016	1.85%	0	0.00%	0	0.00%
Coronary Artery Bypass Graft (CABG)																				
#43 Use of IMA in CABG Surgery	14,665	9,070	61.85%	9,070	0	0.00%	0	0.00%	5,451	37.17%	0	0.00%	0	0.00%	144	0.98%	0	0.00%	0	0.00%
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	10,271	6,217	60.53%	6,217	0	0.00%	0	0.00%	3,951	38.47%	0	0.00%	0	0.00%	103	1.00%	0	0.00%	0	0.00%
Depression																				
#9 Antidepressant Meds During Acute Phase for Patients with New Episode	11,079	7,685	69.37%	7,685	0	0.00%	0	0.00%	802	7.24%	1,748	15.78%	491	4.00%	300	2.71%	173	1.56%	0	0.00%
#106 Patients who have MD Disorder who meet DSM IV Criteria	6,697	3,991	59.59%	3,991	0	0.00%	0	0.00%	342	5.11%	1,877	28.03%	170	3.00%	183	2.73%	253	3.78%	0	0.00%
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	17,091	10,778	63.06%	10,778	0	0.00%	0	0.00%	21	0.12%	3,368	19.71%	233	1.00%	503	2.94%	475	2.78%	0	0.00%

¹ For each measure, the total # of instances where a TIN/NPI combination submitted a QDC for that measure.
² For each measure, the # of instances where a TIN/NPI combination submitted a valid QDC for that measure.
³ The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
⁴ The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.
⁵ The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.
⁶ The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.
⁷ The # of occurrences where a valid NPI is not present.
 Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI).
 Note: Individuals participating in GPRO are excluded from these reports.

Topic Measure	QDC Submission Attempts			Total QDCs Reported on Eligible Cases	Denominator Mismatch ²																Resubmitted QDCs ⁷		Unattributed (No NPI) ⁸	
	Total QDCs Reported ¹	Total Valid QDCs Reported ³	% Valid		Patient Age Mismatch ⁴		Patient Gender Mismatch ⁵		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC							
	#	%	#		%	#	%	#	%	#	%	#	%	#	%	#	%	#	%					
Myelodysplastic Syndrome (MDS) and Acute Leukemias																								
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	11,059	10,313	93.25%	10,313	0	0.00%	0	0.00%	91	0.82%	620	5.61%	10	0.00%	25	0.23%	7	0.06%	0	0.00%	0	0.00%		
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	7,413	6,654	89.76%	6,991	0	0.00%	0	0.00%	71	0.96%	333	4.49%	7	0.00%	11	0.15%	6	0.08%	0	0.00%	0	0.00%		
Medication Management																								
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	10,508	165	1.57%	305	759	7.22%	0	0.00%	1,837	17.48%	0	0.00%	0	0.00%	420	4.00%	0	0.00%	0	0.00%	0	0.00%		
#130 Documentation of Current Medications	1,574,520	1,488,296	94.52%	1,488,296	9	0.00%	0	0.00%	73,574	4.67%	0	0.00%	0	0.00%	12,638	0.80%	0	0.00%	12	0.00%	4	0.00%		
Mental Health																								
#134 Screening for Clinical Depression	11,462	7,045	61.46%	7,045	0	0.00%	0	0.00%	3,347	29.20%	0	0.00%	0	0.00%	1,070	9.34%	0	0.00%	0	0.00%	0	0.00%		
Myeloma																								
#69 Treatment with Bisphosphonates	8,127	7,739	95.23%	7,739	0	0.00%	0	0.00%	68	0.84%	278	3.42%	18	0.00%	22	0.27%	3	0.04%	0	0.00%	0	0.00%		
Myocardial Infarction																								
#28 Aspirin at Arrival	27,059	23,371	86.37%	23,376	0	0.00%	0	0.00%	817	3.02%	2,632	9.73%	105	0.00%	81	0.30%	41	0.15%	0	0.00%	0	0.00%		
Nuclear Medicine																								
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	60,887	59,329	97.44%	59,479	0	0.00%	0	0.00%	1,151	1.89%	0	0.00%	0	0.00%	257	0.42%	0	0.00%	0	0.00%	0	0.00%		
Obesity																								
#128 Universal Weight Screening and Follow-Up	262,920	250,285	95.19%	250,285	0	0.00%	0	0.00%	11,021	4.19%	0	0.00%	0	0.00%	1,614	0.61%	0	0.00%	0	0.00%	0	0.00%		
Oncology																								
#156 Oncology: Radiation Dose Limits to Normal Tissues	985	723	73.40%	723	0	0.00%	0	0.00%	35	3.55%	155	15.74%	61	6.00%	8	0.81%	4	0.41%	0	0.00%	0	0.00%		
#194 Oncology: Cancer Stage Documented	34,788	32,326	92.96%	32,342	0	0.00%	0	0.00%	273	0.79%	1,937	5.57%	74	0.00%	119	0.34%	50	0.14%	0	0.00%	0	0.00%		
Osteoporosis																								
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	5,680	1,778	31.30%	1,778	47	0.83%	0	0.00%	117	2.06%	1,687	29.70%	1,165	21.00%	33	0.58%	1,844	32.46%	0	0.00%	0	0.00%		
#39 Screening or Therapy for Women Aged 65 Years and Older	209,120	192,416	92.01%	192,416	4,799	2.29%	6,336	3.03%	13,188	6.31%	0	0.00%	0	0.00%	3,512	1.68%	0	0.00%	4	0.00%	0	0.00%		
#40 Management Following Fracture	51,585	1,116	2.16%	1,116	442	0.86%	0	0.00%	42	0.08%	46,991	91.09%	2,131	4.00%	54	0.10%	5,148	9.98%	0	0.00%	0	0.00%		
#41 Pharmacologic Therapy	41,649	31,843	76.46%	31,843	350	0.84%	0	0.00%	534	1.28%	7,977	19.15%	837	2.00%	248	0.60%	658	1.58%	0	0.00%	0	0.00%		
Otitis																								
#91 AOE: Topical Therapy	1,717	1,632	95.05%	1,632	0	0.00%	0	0.00%	21	1.22%	44	2.56%	3	0.00%	17	0.99%	2	0.12%	0	0.00%	0	0.00%		
#92 AOE: Pain Assessment	1,311	1,202	91.69%	1,202	0	0.00%	0	0.00%	0	0.00%	62	4.73%	5	0.00%	5	0.38%	10	0.76%	0	0.00%	0	0.00%		
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	1,121	1,074	95.81%	1,075	0	0.00%	0	0.00%	16	1.43%	23	2.05%	0	0.00%	6	0.54%	2	0.18%	0	0.00%	0	0.00%		
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	79	0	0.00%	0	79	100.00%	0	0.00%	0	0.00%	0	0.00%	79	100.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%		
Pain Management																								
#131 Assessment Prior to Initiation of Patient Treatment	159,296	125,367	78.70%	125,367	0	0.00%	0	0.00%	27,831	17.47%	0	0.00%	0	0.00%	6,098	3.83%	0	0.00%	0	0.00%	0	0.00%		
Perioperative																								
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	1,523,275	111,866	7.34%	112,006	83	0.01%	0	0.00%	1,392,225	91.40%	0	0.00%	0	0.00%	19,041	1.25%	0	0.00%	3	0.00%	0	0.00%		
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	105,139	83,161	79.10%	83,161	12	0.01%	0	0.00%	21,187	20.15%	0	0.00%	0	0.00%	791	0.75%	0	0.00%	0	0.00%	0	0.00%		
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	99,028	52,036	52.55%	69,862	6	0.01%	0	0.00%	28,213	28.49%	0	0.00%	0	0.00%	953	0.96%	0	0.00%	0	0.00%	0	0.00%		
#23 VTE Prophylaxis	79,422	62,582	78.80%	62,583	8	0.01%	0	0.00%	16,259	20.47%	0	0.00%	0	0.00%	578	0.73%	0	0.00%	2	0.00%	0	0.00%		
#30 Timing of Prophylactic Antibiotics - Administering Physician	1,502,396	1,181,029	78.61%	1,194,796	83	0.01%	0	0.00%	298,676	19.88%	0	0.00%	0	0.00%	8,924	0.59%	0	0.00%	2	0.00%	0	0.00%		
#45 Discontinuation of Prophylactic Antibiotics	89,100	21,027	23.60%	26,666	5	0.01%	0	0.00%	60,797	68.23%	0	0.00%	0	0.00%	1,637	1.84%	0	0.00%	0	0.00%	0	0.00%		
Pharyngitis																								
#66 Appropriate Testing for Children with Pharyngitis	590	1	0.17%	1	588	99.66%	0	0.00%	0	0.00%	1	0.17%	579	98.00%	0	0.00%	9	1.53%	0	0.00%	0	0.00%		
Pneumonia																								
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	230,638	216,873	94.03%	216,879	4	0.00%	0	0.00%	6,800	2.86%	5,693	2.47%	597	0.00%	824	0.36%	67	0.03%	0	0.00%	1	0.00%		
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	252,487	241,019	95.46%	241,019	4	0.00%	0	0.00%	7,064	2.80%	3,264	1.29%	197	0.00%	902	0.36%	69	0.03%	0	0.00%	0	0.00%		
#59 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	227,023	217,571	95.84%	217,611	2	0.00%	0	0.00%	6,416	2.83%	1,878	0.83%	282	0.00%	790	0.35%	63	0.03%	0	0.00%	0	0.00%		
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	154,953	148,531	95.86%	148,531	2	0.00%	0	0.00%	4,353	2.81%	1,271	0.82%	98	0.00%	661	0.43%	50	0.03%	0	0.00%	0	0.00%		
Pneumonia Pneumococcal																								
#111 Vaccination for Patients 65 years and Older	351,433	323,989	92.19%	324,238	13,588	3.87%	0	0.00%	24,332	6.92%	0	0.00%	0	0.00%	2,863	0.81%	0	0.00%	0	0.00%	0	0.00%		
Preventive Care and Screening																								
#173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening	77,824	75,532	97.05%	75,532	0	0.00%	0	0.00%	1,876	2.41%	0	0.00%	0	0.00%	416	0.53%	0	0.00%	0	0.00%	0	0.00%		
Prostate Cancer																								
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients	2,351	1,469	62.48%	1,523	0	0.00%	0	0.00%	709	30.16%	6	0.26%	72	3.00%	31	1.32%	10	0.43%	0	0.00%	0	0.00%		
#104 Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	1,824	1,326	72.70%	1,372	0	0.00%	0	0.00%	388	21.27%	4	0.22%	34	2.00%	20	1.10%	6	0.33%	0	0.00%	0	0.00%		
#105 Three-dimensional Radiotherapy for Patients with Prostate Cancer	2,195	1,638	74.62%	1,688	0	0.00%	0	0.00%	425	19.36%	14	0.64%	31	1.00%	35	1.59%	2	0.09%	0	0.00%	0	0.00%		
Radiology																								
#145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	330,941	311,513	94.13%	311,524	0	0.00%	0	0.00%	16,576	5.01%	0	0.00%	0	0.00%	2,841	0.86%	0	0.00%	0	0.00%	0	0.00%		
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	668,546	647,828	96.87%	647,680	0	0.00%	0	0.00%	15,090	2.26%	104	0.02%	1,659	0.00%	3,747	0.56%	276	0.04%	0	0.00%	0	0.00%		

¹ For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

² For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

³ The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

⁴ The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

⁵ The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

⁶ The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

⁷ The # of occurrences where a valid NPI is not present.

Note: MCMP and GPG pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Note: Individuals participating in GPRO are excluded from these reports.

Topic Measure	QDC Submission Attempts			Total QDCs Reported on Eligible Cases	Denominator Mismatch ²												Resubmitted QDCs ⁷		Unattributed (No NPI) ⁹			
	Total QDCs Reported ¹	Total Valid QDCs Reported ⁵	% Valid		Patient Age Mismatch ⁴		Patient Gender Mismatch ⁶		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim						Incorrect DX and Only QDC	
	#	#	%		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%		
Stroke and Stroke Rehabilitation																						
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	6,378	5,237	82.11%	5,237	0	0.00%	0	0.00%	403	6.32%	498	7.81%	158	2.00%	66	1.03%	32	0.50%	0	0.00%	0	0.00%
#32 Discharged on Antiplatelet Therapy	8,592	7,375	85.84%	7,375	0	0.00%	0	0.00%	475	5.53%	402	4.68%	143	2.00%	129	1.50%	74	0.86%	0	0.00%	0	0.00%
#35 Screening for Dysphagia	4,233	2,721	64.28%	3,163	0	0.00%	0	0.00%	275	6.50%	471	11.13%	297	7.00%	24	0.57%	9	0.21%	0	0.00%	0	0.00%
#36 Consideration of Rehabilitation Services	6,316	5,315	84.15%	5,327	0	0.00%	0	0.00%	328	5.19%	457	7.24%	95	2.00%	87	1.38%	45	0.71%	0	0.00%	0	0.00%
Syncope																						
#55 ECG Performed for Syncope	658,561	143,363	21.77%	143,366	113,026	17.16%	0	0.00%	4,428	0.67%	382,866	58.14%	124,591	19.00%	492	0.07%	6,865	1.04%	0	0.00%	2	0.00%
Thoracic Surgery																						
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	8,301	132	1.59%	132	0	0.00%	0	0.00%	33	0.40%	21	0.25%	7,153	86.00%	4	0.05%	958	11.54%	0	0.00%	2	0.02%
Tobacco Use																						
#114 Inquiry Regarding Tobacco Use	1,389,039	1,220,911	87.90%	1,325,970	3	0.00%	0	0.00%	56,219	4.05%	0	0.00%	0	0.00%	6,850	0.49%	0	0.00%	0	0.00%	0	0.00%
#115 Advising Smokers to Quit	718,794	665,562	92.59%	687,243	0	0.00%	0	0.00%	27,068	3.77%	0	0.00%	0	0.00%	4,481	0.62%	0	0.00%	2	0.00%	0	0.00%
Upper Respiratory Infection (URI)																						
#65 Appropriate Treatment for Children	402	1	0.25%	1	400	99.50%	0	0.00%	0	0.00%	1	0.25%	392	98.00%	0	0.00%	8	1.99%	0	0.00%	0	0.00%
Urinary Incontinence (UI)																						
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	146,340	127,886	87.39%	127,888	5,512	3.77%	5,843	3.99%	13,730	9.38%	0	0.00%	0	0.00%	4,706	3.22%	0	0.00%	17	0.01%	0	0.00%
#49 Characterization of UI in Women Aged 65 Years and Older	37,183	26,300	70.73%	26,312	1,533	4.12%	1,275	3.43%	696	1.87%	6,122	16.46%	2,605	7.00%	220	0.59%	1,410	3.79%	1	0.00%	0	0.00%
#50 Plan of Care for UI in Women Aged 65 Years and Older	34,025	24,783	72.84%	24,791	1,373	4.04%	1,134	3.33%	685	2.01%	4,827	14.19%	2,229	7.00%	330	0.97%	1,340	3.94%	2	0.01%	0	0.00%
Wound Care																						
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	785	288	36.69%	288	0	0.00%	0	0.00%	52	6.62%	202	25.73%	10	1.00%	20	2.55%	29	3.69%	0	0.00%	0	0.00%
Total	23,965,173	19,271,071	80.41%	19,558,048	606,562	2.53%	16,115	0.07%	2,634,510	10.99%	1,013,937	4.23%	524,192	2.00%	165,801	0.69%	66,129	0.28%	124	0.00%	27	0.00%

¹ For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

² For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

³ The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

⁴ The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

⁵ The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

⁶ The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

⁷ The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Note: Individuals participating in GPRO are excluded from these reports.